Amneal Enters U.S. Respiratory Market with Two Metered-Dose Inhaler Launches
Event summary
- Amneal launched albuterol sulfate and beclomethasone dipropionate HFA metered-dose inhalers in the U.S. on April 14, 2026.
- The products are generic equivalents of PROAIR® HFA and QVAR® Inhalation Aerosol, respectively.
- 2025 FDA approvals enabled the launches, with annual sales potential of $1.8 billion combined.
- Amneal's Ireland facility manufactures these complex formulations, addressing patient access gaps.
The big picture
Amneal's entry into the U.S. respiratory market with metered-dose inhalers marks its expansion into a high-value, complex generic category. The launches address gaps in patient choice, particularly for QVAR®'s discontinued hand-breath actuator device. With $1.8 billion in combined annual sales potential, this move positions Amneal to challenge established players in a market driven by both innovation and affordability.
What we're watching
- Market Penetration
- How Amneal will compete against established brands in the crowded U.S. respiratory market.
- Pipeline Execution
- Whether Amneal can sustain momentum with additional inhalation products in development.
- Regulatory Compliance
- The pace at which Amneal can navigate FDA requirements for complex generic formulations.
Related topics